Cue Biopharma Inc reports results for the quarter ended in December - Earnings Summary

Cue Biopharma

21/03/2023 21:01

* Cue Biopharma Inc  CUE.OQ  reported a quarterly adjusted
loss
of 38 cents​​ per share for the quarter ended in December. The
mean expectation of four analysts for the quarter was for a loss
of 31 cents per share.
    * Revenue fell 98.2% to $151.00 thousand from a year ago;
analysts
expected $103.75 thousand. 
    * Cue Biopharma Inc's reported EPS for the quarter was a
loss
of 38 cents​.
    * The mean earnings estimate of analysts had risen by
about 7.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Cue Biopharma Inc shares had risen by 8.4% this quarter.
    * The company reported a quarterly loss of $14.59 million.
    * Wall Street's median 12-month price target for Cue
Biopharma Inc
is $9.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 21 at 09:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.31          -0.38          Missed
 Sep. 30 2022      -0.38          -0.31          Beat
 Jun. 30 2022      -0.42          -0.37          Beat
 Mar. 31 2022      -0.43          -0.44          Missed